Scarica l'app Stockscreener
45.27
4.18%
-1.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$47.14
Aprire:
$46.75
Volume 24 ore:
1.44M
Relative Volume:
0.17
Capitalizzazione di mercato:
$17.92B
Reddito:
$1.94B
Utile/perdita netta:
$-2.82B
Rapporto P/E:
-6.2341
EPS:
-7.2617
Flusso di cassa netto:
$-2.08B
1 W Prestazione:
-18.76%
1M Prestazione:
-8.86%
6M Prestazione:
+82.87%
1 anno Prestazione:
+62.36%
Intervallo 1D:
$45.15
$47.19
Intervallo di 1 settimana:
$45.15
$56.10
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.19 | 18.70B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
420.54 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
684.58 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
756.65 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.86 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
291.91 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Research Analysts Issue Forecasts for Moderna Q1 Earnings - MarketBeat
Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations - Moomoo
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance Singapore
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? - Yahoo Finance
CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots - Bloomberg Law News
Moderna shares dip amid rising selling pressure - Traders Union
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN? - The Motley Fool
Moderna, Inc. (MRNA) Stock Analysis: Navigating A 52-Week High Amidst Revenue Decline - DirectorsTalk Interviews
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $4.12 Million Position in Moderna, Inc. $MRNA - MarketBeat
M&T Bank Corp Acquires 240,400 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Price Today: Moderna, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Eagle-Tribune
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - News-Press NOW
CureVac sues Moderna over mRNA vaccine patents - Investing.com
Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs - Quiver Quantitative
CureVac sues Moderna over mRNA vaccine patents By Investing.com - Investing.com Canada
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna (MRNA) Expected to Announce Earnings on Friday - MarketBeat
Moderna, Inc. (MRNA) Presents at ESCMID Global 2026Slideshow (NASDAQ:MRNA) 2026-04-23 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
What does smart money think about Moderna (MRNA) stock (+1.11%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - Healthcare Dive
European Commission Approves MRNA's COVID-19-Influenza Combo Shot - Yahoo Finance
Moderna starts late-stage trial for bird flu vaccine - Seeking Alpha
Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… - marketscreener.com
Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) - marketscreener.com
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Moderna Inc. stock (US60770K1034): Does its mRNA pivot beyond COVID now unlock sustainable growth? - AD HOC NEWS
Moderna Inc. (MRNA)Announces Accepted Oncology Clinical Data Presentations at 2026 ASCO Annual Meeting, Schedules Concurrent Investor WebcastFloat Short - UBND thành phố Hải Phòng
Moderna Inc. (MRNA) Secures European Commission Marketing Authorization for World’s First Combined Influenza-COVID mRNA Vaccine mCOMBRIAXCost Structure - UBND thành phố Hải Phòng
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Moderna begins phase 3 trial of H5 bird flu vaccine candidate - Investing.com Canada
Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
Moderna begins late-stage bird flu shot trial in U.S. and UK - Stock Titan
High-Yield Autocallable Notes Linked to Moderna (AMUB) — 1-Year Term - Stock Titan
Europe Clears First Flu/COVID Combo Shot From Moderna - Benzinga
Moderna Receives European Commission Marketing Authorization For mCOMBRIAX - TradingView
Moderna (MRNA) Secures EU Approval for mCOMBRIAX Vaccine - GuruFocus
Moderna: Ec Granted Marketing Authorization f - Moomoo
Moderna (MRNA) Secures EU Approval for mRNA Combination Vaccine - GuruFocus
Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
Moderna wins EC nod for mCOMBRIAX - The Pharma Letter
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - Investing News Network
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
3.17%
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):